Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy

References

• Kariyawasan CC, Hughes DA, Jayatillake MM, et al. Multiple myeloma: causes and consequences of delay in diagnosis. QJM 2007;100:635-40
   PubMed Web of Science ®Google Scholar
• Moreau P, San Miguel J, Ludwig H, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi133-7
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Niesvizky R, et al. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev 2015;41:827-35
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
   PubMed Web of Science ®Google Scholar
• Ludwig H, Sonneveld P, Davies F, et al. European perspective on multiple myeloma treatment strategies in 2014. Oncologist 2014;19:829-44
   PubMed Web of Science ®Google Scholar
• Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits 2015;8:204-15
   PubMed Web of Science ®Google Scholar
• Lipe B, Vukas R, Mikhael J. The role of maintenance therapy in multiple myeloma. Blood Cancer J 2016;6:e485
   PubMed Web of Science ®Google Scholar
• Arikian SR, Milentijevic D, Binder G, et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin 2015;31:1105-15
   PubMed Web of Science ®Google Scholar
• Zhou X, Xia J, Mao J, et al. Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: a retrospective analysis from the Chinese experience. Hematology 2016;21:280-6
   PubMed Web of Science ®Google Scholar
• Blommestein HM, Verelst SG, de Groot S, et al. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. Eur J Haematol 2016;96:198-208
   PubMed Web of Science ®Google Scholar
• Fragoulakis V, Kastritis E, Psaltopoulou T, et al. Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. Cancer Manag Res 2013;5:37-48
   PubMedGoogle Scholar
• Gaultney JG, Franken MG, Tan SS, et al. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Ther 2013;38:41-7
   PubMed Web of Science ®Google Scholar
• Gooding S, Lau IJ, Sheikh M, et al. Double relapsed and/or refractory multiple myeloma: clinical outcomes and real world healthcare costs. PLoS One 2015;10:e0136207
   PubMed Web of Science ®Google Scholar
• Petrucci MT, Calabrese E, Levi A, et al. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. Tumori 2013;99:e193-202
   PubMedGoogle Scholar
• NHS Health Research Authority. What approvals and decisions do I need? London, United Kingdom. Available at: https://www.hra.nhs.uk/approvals-amendments/what-approvals-do-i-need/
   Google Scholar
• European Forum for Good Clinical Practice. The EFGCP report on the procedure for the ethical review of protocols for clinical research projects in Europe. Brussels, Belgium. 2011. Available at: http://www.efgcp.eu/Downloads/EFGCPReportFiles/Italy%20definitive.pdf
   Google Scholar
• International Epidemiological Association. Good Epidemiological Practice (GEP). Raleigh, USA. 2007. Available at: http://ieaweb.org/good-epidemiological-practice-gep/
   Google Scholar
• Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol 2016;175:66-76
   PubMed Web of Science ®Google Scholar
• Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 2016;175:252-64
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE technology appraisal guidance TA129. Bortezomib monotherapy for relapsed multiple myeloma. London, United Kingdom: NICE; 2007. Available at: https://www.nice.org.uk/guidance/ta129
   Google Scholar
• National Institute for Health and Care Excellence. NICE technology appraisal guidance TA171. Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy NICE; London, United Kingdom. 2009. Available at: https://www.nice.org.uk/guidance/ta171
   Google Scholar
• National Institute for Health and Care Excellence. NICE technology appraisal guidance TA338. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib. NICE: London, United Kingdom. 2015. Available at: https://www.nice.org.uk/guidance/TA338
   Google Scholar
• Department of Health. NHS reference costs 2013 to 2014. London, United Kingdom. 2014. Available at: https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014
   Google Scholar
• Service C. Laboratory handbook and price list; a brief guide for clinical and laboratory staff. University of Birmingham; location: Birmingham, United Kingdom. 2010
   Google Scholar
• Press P. MedicinesComplete (online). London. 2018. Available at: http://www.medicinescomplete.com/
   Google Scholar
• L’Assurance Maladie. Classification Commune des Actes Médicaux. Paris, France. Available at: http://www.ameli.fr/accueil-de-la-ccam/trouver-un-acte/rechercher-un-acte.php
   Google Scholar
• L’Assurance Maladie. Base des Médicaments et Infomations Tarifaires. Paris, France. Available at: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI
   Google Scholar
• L’Assurance Maladie. Nomenclature generale des actes professionnels (NGAP) restant en vigueur depuis la decision uncam du 11 mars 2005 presentation. 2017. Paris, France. Available at: https://www.ameli.fr/sites/default/files/Documents/3926/document/ngap_assurance-maladie.pdf
   Google Scholar
• L’Assurance Maladie. Biologie medicale nomencature des actes. 2017. Paris, France. Available at: http://www.codage.ext.cnamts.fr/f_mediam/fo/nabm/DOC.pdf
   Google Scholar
• France Ministry of Health. Echelle Nationale des Coûts. Lyon, France. http://www.atih.sante.fr/
   Google Scholar
• Codifa. Informatore Farmaceutico: Codifa - Informatore Farmaceutico. Milan, Italy. Available at: http://www.codifa.it/
   Google Scholar
• Agenzia Italiana del Farmaco (AIFA). Elenco Medicinali di fascia A e H. Rome, Italy. Available at: http://www.agenziafarmaco.gov.it/it/content/elenco-medicinali-di-fascia-e-h
   Google Scholar
• FILE F – Regione del Veneto. Allegato A alla Dgr n. 95 del 31 gennaio 2012. Venice, Italy. Available at: http://bur.regione.veneto.it/BurvServices/Pubblica/Download.aspx?name=95_AllegatoA_238115.pdf&type=9&storico=False
   Google Scholar
• Ragazzo C. Regione Lombardia capo fila nel File F. Giornale Italiano di Health Technology Assessment 2009;2:119-26
   Google Scholar
• Regione del Veneto. Allegato B al Decreto n. 47 del 22.5.2013. Verona, Italy. Available at: http://www.ospedaleuniverona.it/extfiles/internet/93101/attachment/allegatob.pdf
   Google Scholar
• Dani C, Ravasio R, Fioravanti L, et al. Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatment. It J Pediatr 2014;40:40
   PubMed Web of Science ®Google Scholar
• Garattini L, Castelnuovo E, Lanzeni D, et al. Durata e costo delle visite in medicina generale: il progetto DYSCO. Farmecon Health Econ Ther Path 2003;4:109-14
   Google Scholar
• Tarricone R, Torbica A, Franzetti F, et al. Hospital costs of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. Cost Effect Resour Allo 2010;8:8
   PubMedGoogle Scholar
• Vitale C, Bagnis C, Marangella M, et al. Cost analysis of blood purification in intensive care units: continuous versus intermittent hemodiafiltration. J Nephrol 2003;16:572-9
   PubMed Web of Science ®Google Scholar
• Oncomip. Référentiel Traitement Myélome Multiple. updated 2011. Toulouse, France. Available at: http://www.oncomip.org
   Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Levact. London, United Kingdom. 2011. . Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Levact/human_referral_000199.jsp&mid=WC0b01ac0580024e9a
   Google Scholar
• Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010;10:21-7
   PubMed Web of Science ®Google Scholar
• National Health Service Commissioning Board. National Cancer Drugs Fund List. London, United Kingdom. 2013. . Available at: https://www.england.nhs.uk/wp-content/uploads/2013/03/ncdf-list.pdf
   Google Scholar
• Celgene. Revlimid (lenalidomide) summary of product characteristics. Uxbridge, United Kingdom. 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf
   Google Scholar
• Janssen-Cilag. Velcade^® (bortezomib) summary of product characteristics. Beerse, Belgium. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000539/WC500048471.pdf
   Google Scholar
• Acaster S, Gaugris S, Velikova G, et al. Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. Support Care Cancer 2013;21:599-607
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Kumar SK, Srivastava G, et al. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. Am J Hematol 2014;89:302-5
   PubMed Web of Science ®Google Scholar
• Gao SQ, Chen Y, Liu Q, et al. Direct medical costs associated with multiple myeloma in Chinese patients: estimations from China public health insurance claim data. Value Health 2015;18:A447-8
   PubMed Web of Science ®Google Scholar
• Potluri R, Farr AM, Hirji I, et al. Treatment sequencing patterns and costs of care in patients with relapsed/refractory multiple myeloma. Value Health 2015;18:A450
   PubMedGoogle Scholar
• Amgen Europe B.V. Kyprolis (carfilzomib) summary of product characteristics. Uxbridge, United Kingdom. 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003790/WC500197692.pdf
   Google Scholar
• Bristol-Myers Squibb. Empliciti (elotuzumab): summary of product charateristics. 2016. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003967/WC500206673.pdf
   Google Scholar
• Janssen-Cilag. DARZALEX (daratumumab): summary of product characteristics. Beerse, Belgium. 2016. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004077/WC500207296.pdf
   Google Scholar